PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
46.54
+0.66 (1.44%)
Jan 3, 2025, 4:00 PM EST - Market closed
PTC Therapeutics Employees
As of December 31, 2023, PTC Therapeutics had 1,055 total employees, including 988 full-time and 67 part-time employees. The number of employees decreased by 355 or -25.18% compared to the previous year.
Employees
1,055
Change (1Y)
-355
Growth (1Y)
-25.18%
Revenue / Employee
$853,710
Profits / Employee
-$429,574
Market Cap
3.59B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
PTCT News
- 12 days ago - PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 16 days ago - PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia - PRNewsWire
- 18 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - PTC Therapeutics Stock Soars on Novartis Licensing Agreement - Investopedia
- 4 weeks ago - PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program - Benzinga
- 4 weeks ago - PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis - Reuters
- 4 weeks ago - PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program - PRNewsWire
- 5 weeks ago - PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs - Benzinga